The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia - Full Text View

Sponsor:	University of Pittsburgh
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002276

Purpose

To determine if platelet dysfunction and/or pharmacologic drug interaction occurs in patients taking both AZT and ibuprofen, which might account for enhanced bleeding tendency.

Condition	Intervention
HIV Infections Hemophilia A	Drug: Ibuprofen Drug: Zidovudine

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs

Resource links provided by NLM:

Genetics Home Reference related topics: hemophilia Help Me Understand Genetics

MedlinePlus related topics: AIDS Hemophilia

Drug Information available for: Ibuprofen Zidovudine

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	12 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients must have:

Hemophilia.
HIV-seropositivity confirmed by Western Blot.

Prior Medication:

Required:

- AZT for study patients.

Allowed:

- Ibuprofen.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

Hospitalization for opportunistic infection, bacterial infection or malignancy.

Concurrent Medication:

Excluded:

AZT (for control group).
Antibiotics or other medication for opportunistic infection, bacterial infection, or malignancy.

Patients with the following prior conditions are excluded:

Hospitalization for opportunistic infection, bacterial infection, or malignancy.

Required:

Ibuprofen.
AZT 1-2 gm daily (for study patient) or not taking AZT (for control).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002276

Locations

United States, Pennsylvania
Hemophilia Ctr of Western PA / Univ of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15219

Sponsors and Collaborators

University of Pittsburgh

More Information

Publications:

Ragni MV, Miller BJ, Whalen R, Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. Am J Hematol. 1992 Jul;40(3):176-82.

Study ID Numbers:	044A
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00002276 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Blood Platelets
Ibuprofen
Drug Interactions
Zidovudine
Hemophilia A

Additional relevant MeSH terms:

Antimetabolites
Anti-Inflammatory Agents
Anti-Infective Agents
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Hemophilia A
Zidovudine
Infection
Reverse Transcriptase Inhibitors
Hemorrhagic Disorders
Anti-Retroviral Agents
Sensory System Agents
Therapeutic Uses

Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Retroviridae Infections
Nucleic Acid Synthesis Inhibitors
RNA Virus Infections
Ibuprofen
Anti-HIV Agents
Immune System Diseases
Hematologic Diseases
Coagulation Protein Disorders
Blood Coagulation Disorders
Cyclooxygenase Inhibitors
Acquired Immunodeficiency Syndrome
Enzyme Inhibitors
Antiviral Agents

ClinicalTrials.gov processed this record on February 08, 2010